As we get ready for CorMedix, Inc. (NYSE:CRMD) earnings, we have an opportunity to take a quantitative approach to preparation. The company’s first numbers are slated to hit the wires after market close (confirmed) on May 11, 2017. Hence, it’s a good time to take a thorough look at the company’s historical behavior around earnings, as well as where current expectations stand for performance in the quarter.
CorMedix, Inc. (NYSE:CRMD) Historical Stock Behavior Data for Earnings Reports
According to market and research data, the company’s average earnings surprise was -46.45 percent, when looking at the prior year. Let’s look at how these four reports worked out in detail.
The company put up an EPS number of -0.13 on March 16, 2017. That missed the consensus expectation of $-0.11, representing a Negative surprise of -18.18% That report showed a top line number of $0.12M, which compares to a consensus estimate of $0.14M. In reaction, the stock dropped -13.04% on the next day. A week later, the price change was -15.94%.
The company put up an EPS number of $-0.23 on March 16, 2017. That compared with a consensus expectation of $-0.15, representing a Negative surprise -53.33%. That report also showed a top line number of $0.03M, which compares to a consensus estimate of $0.07M put out by analysts ahead of the report. That spurred a move of -13.04% a day later. Seven days after that, the stock had posted a net move of -15.94%.
If we look back at November 09, 2016, we see a company able to log an EPS print of $-0.09. That topped the projected outlook of $-0.10, handing the market a Negative surprise of -14.29%. Sales came in at $0M, which countered expectations of $0.08M, leading to a net move in shares of -18.14% the following day, and -24.34% seven days out.
Finally, on August 05, 2016, we saw a Negative surprise of -100.00% when the company came to the table with an EPS of $-0.23, answering analysts at $-0.12 on the bottom line. The top line hit at $0.05M (versus $0.05M).
CorMedix, Inc. (NYSE:CRMD): What’s the Word on the Street?
This time around, Q1 is expected to offer up an EPS point of $-0.16, with a range of $-0.16-$-0.15. The top line expectation range out from analysts right now is at $60k-$60k, pushing a mean of $60k.
Shares of CorMedix, Inc. (NYSE:CRMD) printed a last close of $0.64, which pushes the total market value of the company to roughly $42.30M. Where is it headed from here? It’s impossible to say, but analysts currently have a consensus 12-month target out right now at $5.25.
Looking at recent action, we’ve seen shares declined -85.78% off trailing year highs, but advance overall 1 a ytd basis. The stock has been bouncing in a recent range defined by the $0.6252-$0.6800 levels, with transactions averaging about 3,497,275 shares per day. Over about the past week, the stock has moved nearly -43.35% higher, representing a total gain of -35.34% off its 52-week low.
Finally, the summary performance stats on reporting suggest that there is roughly a 70 percent chance that the stock down in reaction to its next quarterly data peek. If we dig a bit deeper, we can see that shares of the stock saw gains about down 7 out of 10 quarters on recent record. As far as the actual results, the company has “beaten the number” at a rate of roughly 25% over its past 12 reports. On the other hand, the company swung and missed 6 times, with 2 instances of inline data. At present, the company’s stock price per share has shifted about -49.8% percent since the last time it turned in a report card, when it was printing orders around $2.07/share.